

### The 7th International Electronic Conference on Medicinal Chemistry (ECMC 2021) 01–30 NOVEMBER 2021 | ONLINE

Biological evaluation of 4,5,7-trisubstituted Indeno[1,2-b]indoles reveals a potent inhibitor of Protein Kinase CK2 in tumor cells with diverse anti-cancer effects and preferential cytoplasmic localization

Robin Birus <sup>1</sup>, Ehab El-Awaad <sup>1,2,\*</sup>, Laurens Ballentin <sup>1</sup>, Faten Alchab <sup>3,4</sup>, Dagmar Aichele <sup>1</sup>, Laurent Ettouati <sup>5</sup>, Claudia Götz <sup>6</sup>, Marc Le Borgne <sup>7</sup>, and Joachim Jose <sup>1</sup>

- <sup>1</sup> Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, Westfälische Wilhelms-Universität Münster, Corrensstr. 48, 48149 Münster, Germany;
- <sup>2</sup> Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt;
- <sup>3</sup> EA 4446 Bioactive Molecules and Medicinal Chemistry, Faculté de Pharmacie-ISPB, SFR Santé Lyon-Est CNRS UMS3453-INSERM US7, Université Claude Bernard Lyon 1, Université de Lyon, F-69373 Lyon, France;
- <sup>4</sup> Faculty of Pharmacy, Manara University, Latakia, Syria;
- <sup>5</sup> CNRS UMR 5246 Institut de Chimie et Biochimie Moléculaires et Supramoléculaires (ICBMS), Faculté de Pharmacie, ISPB, Université Lyon 1, Université de Lyon, 8 Avenue Rockefeller, F-69373, Lyon, Cedex 08, France;
- <sup>6</sup> Universität des Saarlandes Medizinische Biochemie und Molekularbiologie Geb. 44/45 D-66424 Homburg, Germany;
- <sup>7</sup> Small Molecules for Biological Targets Team, Centre de recherche en cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ Lyon, Lyon, 69373, France.



Biological evaluation of 4,5,7-trisubstituted Indeno[1,2-b]indoles reveals a potent inhibitor of Protein Kinase CK2 in tumor cells with diverse anti-cancer effects and preferential cytoplasmic localization





#### Abstract:

The highly pleiotropic and constitutively active serine/threonine protein kinase CK2 is considered a key target in cancer. The indeno[1,2-*b*]indole scaffold was previously shown to provide derivatives exhibiting strong CK2 inhibition and satisfactory drug-like characteristics. In this work, we evaluated one 4,5,7-trisubstituted indeno[1,2-*b*]indole derivative for its intracellular inhibition of CK2 activity and the accompanying effects on proliferation, migration and apoptosis in cancer cells. The compound 5-isopropyl-4-methoxy-7-methyl-5,6,7,8-tetrahydro-indeno[1,2-*b*]indole-9,10-dione (**5a-2**) strongly inhibited CK2 activity *in vitro* with IC<sub>50</sub> value of 25 nM and in cultured A431, A549 and LNCaP cell lines (> 75% inhibition at 20  $\mu$ M). The intracellular inhibition of CK2 by **5a-2** was comparable to that induced by the reference CK2 inhibitor CX-4945, though the latter exhibited > 6-fold higher inhibitory potency toward CK2 *in vitro* (IC<sub>50</sub> = 3.7 nM). A possible explanation for this discrepancy is the significantly higher intracellular concentrations of **5a-2** compared to CX-4945 following their cellular uptake. Compared to CX-4945, **5a-2** induced similar anti-proliferative, weaker pro-apoptotic but stronger anti-migratory effects on cancer cells. These variations can be partly attributed to the observed differences in the subcellular localization of both compounds whereby 71% of the uptaken **5a-2** molecules were found in the cytoplasm while 49% of intracellular CX-4945 was detectable in the nuclear fraction.

Our study emphasizes the potential of indeno[1,2-*b*]indole as an interesting framework for developing potent CK2 inhibitors and highlights the significance of subcellular distribution in dictating preferential cellular effects of CK2 inhibitors.

Keywords: Anti-cancer; CK2; Indeno[1,2-b]indole; Live cell imaging; Subcellular distribution



### Introduction

- Human CK2 is a constitutively active serine/threonine kinase.
- Shows ubiquitous expression and high pleiotropy (> 500 substrates) with a tightly regulated subcellular localization.
- Well-established therapeutic target in cancer.





- indeno[1,2-b]indole scaffold is a flat tetracyclic structure allowing diverse derivatization of the ring system.
- Several derivatives were identified as potent CK2 inhibitors addressing the ATP-binding pocket of the kinase.



Results and discussion - Inhibition of human CK2 by trisubstituted indeno[1,2-b]indoles and the reference compound CX-4945 *in vitro* 



- Compounds 5a-2 and 5b-2 are potent CK2 inhibitors while their regioisomers
   (5a-1 and 5b-1) are not.
- A methoxy group in position
  4 of the indeno[1,2-b]indole
  scaffold is more favorable
  for CK2 inhibition than in
  position 1.

| Compound | R <sub>1</sub>                   | R <sub>2</sub>    | R <sub>3</sub>    | Inhibition (%)<br>10 μM | IC <sub>50</sub> (μM) <sup>+</sup> |
|----------|----------------------------------|-------------------|-------------------|-------------------------|------------------------------------|
| 5a-1     | -CH <sub>3</sub>                 | -H                | -OCH <sub>3</sub> | 55                      | 8.170                              |
| 5a-2     | -CH <sub>3</sub>                 | -OCH <sub>3</sub> | -H                | 100                     | 0.025                              |
| 5b-1     | -CH <sub>2</sub> CH <sub>3</sub> | -H                | -OCH <sub>3</sub> | 50                      | 9.910                              |
| 5b-2     | -CH <sub>2</sub> CH <sub>3</sub> | -OCH <sub>3</sub> | -H                | 100                     | 0.047                              |
| CX-4945  |                                  |                   |                   | 100                     | 0.0037‡                            |

<sup>†</sup> Values were derived from dose-response curves with nine different inhibitor concentrations determined in a capillary electrophoresis (CE)-based kinase activity assay.

‡ Previously reported by Gozzi et al. J. Med. Chem, 58: 265–277 (2015).



## Results and discussion - Intracellular inhibition of CK2 activity in three different cancer cell lines



CK2 activity was determined in the soluble fraction of lysates from cultured cells treated for 24 h with 5a-2, 5b-2 or CX-4945 at the given concentrations using the previously developed CE-based kinase activity assay.

Compound **5a-2** interferes strongly with intracellular CK2 activity to the same extent as

**CX-4945** despite their different  $IC_{50}$  values.



# Results and discussion - Investigation of the cellular uptake of compounds 5a-2 and CX-4945

 Intracellular concentrations of 5a-2 are > 3-fold higher than those of CX-4945.

Higher intracellular concentration of 5a-2 could provide an explanation for the comparable inhibitory effects of 5a-2 and CX-4945 on cellular CK2 activity, despite the higher IC<sub>50</sub> value of 5a-2.



- Cultured A431 cells were treated with the inhibitors at the given concentrations for 5 h.
- Inhibitor concentrations in the lysates of treated cells were quantified using HPLC-MS/MS.

# Results and discussion - Evaluation of anti-cancer activity (Effect on cell proliferation)



**5a-2** inhibits the growth of 3D tumor spheroids similar to **CX-4945** up to 48 h post-treatment.



# Results and discussion - Evaluation of anti-cancer activity (Effects on cell migration and apoptosis)



- A431 cells were cultured in 96-well plates to a confluence of 30%.
- Cells were treated with the indicated concentrations of each compound while control wells received 1% DMSO.
- IncuCyte<sup>®</sup> caspase 3/7 green reagent (5 μM) was added and the apoptotic cell count depicted from the green fluorescent signals was monitored for 48 h using IncuCyte<sup>®</sup> S3 live cell imaging system.
- The apoptotic cell counts in control wells were subtracted as background from those in treated wells.

**5a-2** exhibits remarkably stronger anti-migratory but weaker pro-apoptotic effects compared to **CX**-



- A549 cells were cultured in 96-well Imagelock plates to a confluence of 100% and a scratch wound was created in each well using an IncuCyte<sup>®</sup> WoundMaker tool (Sartorius).
- Cells were treated with 10  $\mu$ M Of either CX-4945 or 5a-2 while control wells received 1% DMSO.
- Cell migration into the "wound" was monitored for 48 h using an IncuCyte<sup>®</sup> S3 Live Cell Imaging system (Sartorius).

#### **4945**.



## Results and discussion - Investigation of the subcellular distribution of compounds 5a-2 and CX-4945

Following uptake, 5a-2 exhibits preferential а subcellular distribution in the cytoplasm (approx. 71 %) while CX-4945 is mainly localized in the nuclear fraction of the treated cells (approx. 49 %).



Cellular fractions of LNCaP cell lysates were separated and collected by differential centrifugation after 5 h of treatment of cultured cells with 1 µM of 5a-2 or CX-4945.
 The inhibitors were detected in each fraction using HPLC-MS/MS.



#### Conclusions

- The trisubstituted indeno[1,2-*b*]indole derivative **5a-2** demonstrates a strong inhibition of protein kinase CK2 activity in different cancer cell lines.
- Cellular uptake of **5a-2** is more efficient than that of **CX-4945**, probably due to more favorable physicochemical properties and/or different uptake mechanism(s).
- **5a-2** shows prominent anti-migratory and anti-proliferative effects but induces weaker pro-apoptotic effect as compared to **CX-4945**.
- For a highly pleiotropic and ubiquitously expressed target, like CK2, the subcellular distribution of the inhibitors can be determinant for their preferential cellular effects in cancer cells.

